Stage 3A breast cancer is a locally advanced cancer that has spread to nearby lymph nodes but has not reached distant organs. It’s defined by two possible scenarios: either the tumor is any size and has spread to 4 to 9 lymph nodes, or the tumor is larger than 5 centimeters and has spread to 1 to 3 lymph nodes. The five-year relative survival rate for regional breast cancer (which includes stage 3A) is 87 percent, though individual outcomes vary significantly depending on the tumor’s biology and how it responds to treatment.
How Stage 3A Is Defined
Breast cancer staging uses tumor size and lymph node involvement to classify how far the disease has progressed. Stage 3A sits in the “locally advanced” category, meaning the cancer has moved beyond the breast into the lymph node system but hasn’t traveled to distant sites like the bones, lungs, liver, or brain.
There are two combinations that qualify as stage 3A. In the first, the primary tumor can be any size, including cases where no distinct tumor mass is found in the breast itself, but cancer cells have reached 4 to 9 axillary lymph nodes (those under the arm) or the internal mammary nodes near the breastbone. In the second, the tumor is larger than 5 centimeters, but only 1 to 3 lymph nodes are involved. Both patterns reflect cancer that has begun to spread locally but is still considered treatable with curative intent.
Why Tumor Biology Matters as Much as Stage
Two people with stage 3A breast cancer can have very different treatment plans and outlooks depending on three biological markers tested on the tumor: estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 protein levels. These markers tell doctors what’s fueling the cancer’s growth and which therapies are most likely to work.
Tumors that are hormone receptor positive (meaning they grow in response to estrogen or progesterone) can be treated with hormone-blocking therapies after initial treatment. Tumors that overproduce the HER2 protein respond to targeted drugs that shut down that specific growth signal. Cancers that test positive for both hormone receptors and HER2 (“triple positive”) tend to behave less aggressively. In one study comparing these subtypes, the five-year overall survival rate was 96.7 percent for triple-positive patients compared to 82.7 percent for those whose tumors were HER2-positive but hormone receptor negative. The risk of recurrence and death was also significantly higher in the HER2-positive, hormone receptor-negative group.
Triple-negative breast cancer, which lacks all three markers, has fewer targeted treatment options and generally carries a more guarded prognosis. Your oncologist will use these biological details alongside the stage to build a treatment plan tailored to your specific cancer.
Treatment Usually Starts Before Surgery
For stage 3A breast cancer, treatment often begins with systemic therapy (chemotherapy, targeted therapy, or hormone therapy) given before surgery. This approach, called neoadjuvant therapy, serves several purposes. It can shrink the tumor enough to make surgery easier or even allow breast-conserving surgery instead of a full mastectomy. It also gives doctors a real-time window into how well the cancer responds to treatment. If the tumor shrinks dramatically or disappears entirely, that’s a strong signal the therapy is working.
The most common neoadjuvant chemotherapy approach uses a combination of two drug classes given in sequence, typically over four to six months total. For HER2-positive cancers, targeted therapy is added alongside chemotherapy. For hormone receptor-positive cancers, hormone-blocking treatment is part of the overall plan as well, sometimes used during the neoadjuvant phase and almost always continued long-term after surgery. Doctors aim to complete the full planned course of treatment even if the tumor responds quickly, because finishing the regimen gives the best chance of eliminating microscopic cancer cells that imaging can’t detect.
Surgical Options
After neoadjuvant therapy, surgery removes whatever cancer remains. The two main options are mastectomy (removing the entire breast) and lumpectomy (removing only the tumor and a margin of surrounding tissue, also called breast-conserving surgery).
Whether lumpectomy is feasible depends on several factors: how much the tumor shrank during treatment, the size of the remaining tumor relative to the breast, whether cancer exists in multiple locations within the breast, and whether you’re a candidate for the radiation therapy that always follows lumpectomy. If neoadjuvant therapy successfully reduces a large tumor to a small area, lumpectomy may become an option even when it wasn’t at diagnosis. Reasons a person might choose mastectomy include multiple tumor sites in different parts of the breast, a large tumor relative to breast size, a genetic mutation that raises the risk of new cancers, or a preference to avoid the radiation and ongoing surveillance that come with lumpectomy.
Radiation After Surgery
Radiation therapy is a standard part of stage 3A treatment regardless of surgical approach. After mastectomy, radiation targets the chest wall and nearby lymph node regions to reduce the chance of local recurrence. After lumpectomy, it targets the remaining breast tissue and often the lymph nodes as well.
A typical course runs about five to six weeks, with treatments given once daily on weekdays. Each session is brief, usually lasting only a few minutes of actual radiation delivery, though the setup and positioning take longer. If surgical margins were very close or positive (meaning cancer cells were found at the edge of the removed tissue), additional targeted radiation to the scar area may be added.
What Recurrence Risk Looks Like
Stage 3A carries a meaningful risk of recurrence, which is why treatment is aggressive and follow-up is close. Recurrence can be local (in or near the original site), regional (in nearby lymph nodes), or distant (in other organs). The risk is highest in the first five years after treatment but continues at a lower level for years beyond that, particularly for hormone receptor-positive cancers, which can recur a decade or more later.
Modern treatments have improved outcomes considerably compared to older data. The 87 percent five-year survival rate for regional breast cancer reflects current therapies, including targeted drugs and improved chemotherapy combinations that weren’t available in earlier decades. Hormone receptor-positive patients who stay on long-term hormone-blocking therapy further reduce their recurrence risk. Your specific risk depends on how completely the cancer responded to neoadjuvant therapy, the tumor’s biological subtype, and the number of lymph nodes involved.
Follow-Up After Treatment
Once active treatment ends, you enter a structured surveillance schedule. The typical pattern involves visits with your cancer care team every three to six months during the first two years, then every six to twelve months through year five. After five years, annual visits are standard. You’ll have a physical exam at each visit, and mammograms are recommended annually for the remaining breast tissue (after lumpectomy) or the opposite breast.
If you were prescribed hormone-blocking therapy, you’ll continue taking it daily for five to ten years depending on your specific situation. Side effects from these medications, including joint stiffness, hot flashes, and fatigue, are common and worth discussing with your care team since there are often ways to manage them. Many survivorship care plans also include recommendations for maintaining a healthy weight, staying physically active, and monitoring for long-term side effects of chemotherapy and radiation.